Johnson & Johnson’s consumer health unit Kenvue looks set to raise $3.8 billion in an upsized initial public offering (IPO), valuing the business at around $41 billion
Trusted Johnson & Johnson brands including Tylenol, Aveeno, Neutrogena, Listerine, and Band-Aid are set to fall under the new, independent company name in a next-chapter move of repurpo
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh